TEDOVANCT04713514
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Study completion date changed from estimate of Dec 31, 2026 to Nov 9, 2026
Notable Eligibility criteria expanded, about 41 words Show 9 more changesShow less
- Study completion pushed from Dec 2025 to Dec 31, 2026
- Enrollment target: estimated 180 to confirmed 185
- Study sites: 40 to 41
- Primary completion date changed from estimate of Dec 2025 to Dec 15, 2025
- Interventions: OSE2101 (Drug), Pembrolizumab 25 MG/ML [Keytruda] (Drug) to OSE2101 (Drug), Pembrolizumab 25 MG/ML [Keytruda] (Drug)
- Secondary endpoints: details revised at 4 of 5 entries
- Collaborators: details revised at 1 of 2 entries
- Publications: details revised at 1 of 1 entry
- Study description expanded, about 3 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 43 to 40
- Minor Study sites: 42 to 43v14
- Minor Site contacts updated at 1 of 42 sitesv13
Show 10 earlier versionsHide 10 earlier versions
- Notable Eligibility criteria shortened, about 19 words
- Study sites: 38 to 42
- Primary and study completion dates: Jun 2025 to Dec 2025
- Minor Study sites: 29 to 38v10
- Minor Site details revised at 5 of 29 sitesv9
- Notable Eligibility criteria expanded, about 19 words
- Site details revised at 4 of 29 sites
- Notable Eligibility criteria expanded, about 61 words
- Study sites: 28 to 29
- Study description shortened, about 10 words
- Minor Site details revised at 4 of 28 sitesv6
- Notable Eligibility criteria revisedv5
- Notable Eligibility criteria shortened, about 23 words
- Study sites: 26 to 28
- Primary and study completion dates: Mar 2025 to Jun 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Mar 2021 to Aug 5, 2021
- Site details revised at 26 of 26 sites
- Minor Secondary endpoints revised (5)v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Observational arm (Standard of care)
OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years. OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion.
OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
Drugs: OSE2101, Pembrolizumab 25 MG/ML [Keytruda]
Sites
41 sites in 3 countries
France 32, Germany 6, Belgium 3